About
AminoAnalytica builds an AI-based protein-engineering platform using predictive AI and physics-based simulations to optimize enzymes, peptides, and other proteins for pharmaceutical companies. It also targets biotech and biodefense users with rapid workflows for point-of-care diagnostics, emphasizing development in weeks rather than 12+ months.
Market
AminoAnalytica competes in AI-enabled protein-engineering and generative-biology software for pharmaceutical and industrial biotech applications, using computational prediction to reduce traditional trial-and-error experimentation. Its positioning is an end-to-end, scientist-facing platform that combines protein language models, simulations, autonomous workflows, and programmatic access, rather than offering only a foundation model or a single therapeutic-discovery program. Relative to competitors such as Cradle, Generate:Biomedicines, EvolutionaryScale, Profluent, and Absci, its apparent differentiation is broad optimization across enzymes, peptides, and other proteins with accessible platform workflows and CLI integration; comparative performance claims are not established by the available evidence.
AminoAnalytica targets pharmaceutical and industrial biotechnology companies that engineer enzymes, peptides, therapeutic proteins, or related biomolecules. The primary users and buyers are protein-engineering scientists and R&D teams; the evidence does not specify a particular company-size segment, but the platform is aimed at organizations with active protein-development programs.
At a Glance
Problem
AminoAnalytica targets the slow, fragmented process of engineering useful proteins. Protein engineers often have to stitch together many specialized tools and run large numbers of laboratory tests before they can identify a viable candidate; the company describes the existing workflow as taking 12 or more months for emerging-threat diagnostics, while its platform description says it can reduce the need for thousands of lab tests. The resulting pain is primarily time, experimental cost, and scarce bioinformatics capacity.
The clearest high-value use case is biodefense: developing validated point-of-care molecular diagnostics for emerging biological threats in weeks rather than a year or more. The same underlying capability is aimed at designing protein therapeutics, enzymes, peptides, and other engineered proteins, where faster iteration can materially shorten discovery programs.
Product / Service
AminoAnalytica’s core product is Amina, an AI agent for end-to-end protein engineering. Instead of manually assembling computational pipelines, a scientist describes the desired protein and its purpose in plain English. Amina combines more than 50 specialized tools through a no-code interface, draws on scientific literature and the company’s experience engineering proteins, selects and chains tools, interprets results, flags potential problems, and suggests optimizations.
The service is available through a web experience and programmatically through the Amina CLI, including integrations with third-party AI agents and coding assistants. AminoAnalytica offers the product for free to try, while its terms describe the underlying computational infrastructure as a cost-recovery service that passes through actual compute costs without markup. The intended benefit is to function like an additional computational protein engineer, reducing dependence on fragmented workflows and accelerating candidate design.
Market
AminoAnalytica competes in AI-native protein engineering, computational protein design, and biotech software, with an additional positioning in autonomous biodefense and molecular diagnostics. Its competitive set includes Cradle, which offers AI protein-engineering software for pharma and industrial biology; Profluent, which uses AI to author proteins for therapeutics and industrial enzymes; and Generate Biomedicines, which applies generative machine learning to create protein medicines. EvolutionaryScale is another adjacent platform focused on helping scientists understand, imagine, and create proteins.
The company appears to be an early commercial-stage startup rather than clearly pre-revenue. YC lists it as founded in 2024, part of Summer 2024, active, and staffed by three people in London; it launched Amina publicly in July 2025 and invited biotech and pharma users to try it for free. AminoAnalytica also claims experience engineering thousands of proteins for customers. Third-party company databases report approximately $500,000 in funding and estimated revenue of $342,220, but the evidence does not provide a verified customer list or independently audited financials, so the scale of traction remains uncertain.
Founders & Leadership
Funding History
Y Combinator
Recent News
Y Combinator’s biotech directory lists AminoAnalytica as an active S2024 startup with three employees in London. The listing provides a recent public company profile, although its accompanying description appears potentially inconsistent with AminoAnalytica’s protein-engineering positioning.
AminoAnalytica’s official terms page documents the Amina CLI, describing it as a command-line interface that provides programmatic access to the company’s platform. This is evidence of a product/API capability rather than a separate partnership announcement.
Y Combinator described Amina as an AI agent for end-to-end protein engineering and said users can design novel therapeutics through conversation. This is the clearest dated product-focused public announcement found in the evidence.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
AminoAnalytica provides computational infrastructure for protein design on a cost-recovery basis, passing compute costs through to customers. It offers a free, no-setup trial and provides additional credits when users need them.